Back to Search
Start Over
Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study
- Publication Year :
- 2021
- Publisher :
- Oxford University Press, 2021.
-
Abstract
- Introduction This study aims to assess the association of piperacillin/tazobactam and meropenem minimum inhibitory concentration (MIC) and beta-lactam resistance genes with mortality in the MERINO trial. Methods Blood culture isolates from enrolled patients were tested by broth microdilution and whole genome sequencing at a central laboratory. Multivariate logistic regression was performed to account for confounders. Absolute risk increase for 30-day mortality between treatment groups was calculated for the primary analysis (PA) and the microbiologic assessable (MA) populations. Results In total, 320 isolates from 379 enrolled patients were available with susceptibility to piperacillin/tazobactam 94% and meropenem 100%. The piperacillin/tazobactam nonsusceptible breakpoint (MIC >16 mg/L) best predicted 30-day mortality after accounting for confounders (odds ratio 14.9, 95% confidence interval [CI] 2.8–87.2). The absolute risk increase for 30-day mortality for patients treated with piperacillin/tazobactam compared with meropenem was 9% (95% CI 3%–15%) and 8% (95% CI 2%–15%) for the original PA population and the post hoc MA populations, which reduced to 5% (95% CI −1% to 10%) after excluding strains with piperacillin/tazobactam MIC values >16 mg/L. Isolates coharboring extended spectrum β-lactamase (ESBL) and OXA-1 genes were associated with elevated piperacillin/tazobactam MICs and the highest risk increase in 30-day mortality of 14% (95% CI 2%–28%). Conclusions After excluding nonsusceptible strains, the 30-day mortality difference from the MERINO trial was less pronounced for piperacillin/tazobactam. Poor reliability in susceptibility testing performance for piperacillin/tazobactam and the high prevalence of OXA coharboring ESBLs suggests that meropenem remains the preferred choice for definitive treatment of ceftriaxone nonsusceptible Escherichia coli and Klebsiella.
- Subjects :
- 0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
medicine.medical_treatment
030106 microbiology
Population
Microbial Sensitivity Tests
Extended Spectrum Beta-Lactamase
Tazobactam
Meropenem
beta-Lactamases
03 medical and health sciences
Minimum inhibitory concentration
0302 clinical medicine
Internal medicine
medicine
polycyclic compounds
Humans
030212 general & internal medicine
Mortality
Piperacillin-Tazobactam
education
education.field_of_study
business.industry
Bloodstream infection
Extended spectrum beta-lactamase
Piperacillin-tazobactam
Bloodstream Infection
Reproducibility of Results
biochemical phenomena, metabolism, and nutrition
bacterial infections and mycoses
Anti-Bacterial Agents
Piperacillin, Tazobactam Drug Combination
Infectious Diseases
Piperacillin/tazobactam
Beta-lactamase
Ceftriaxone
bacteria
business
medicine.drug
Piperacillin
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....1beaa9ae6f053be65cfd8c244a65656b